Optimized structured treatment interruption for HIV therapy and its performance analysis on controllability

IEEE Transactions on Biomedical Engineering

Volumn 53, Issue 3, 2006, Pages 380-386

  Ko, Ji Hyun ^a,b,c   Kim, Won Hee ^b,d   Chung, Choo Chung ^a,b,e,f  

^a IEEE   (South Korea)

^b Hanyang University   (South Korea)

^c MCGILL UNIVERSITY   (Canada)

^d Samsung Advanced Institute of Technology (SAIT)   (South Korea)

^e Department of Electrical and Biomedical Engineering ^*  (South Korea)

^f Control Theory Study Society of ICASE ^*  (South Korea)

Author keywords

Controllability; Dynamic programming; HIV; MPC; Optimal control; STI

Indexed keywords

CONTROLLABILITY; DISEASES; DYNAMIC PROGRAMMING; IMMUNOLOGY; MEDICAL APPLICATIONS; OPTIMAL CONTROL SYSTEMS;

HIV; MPC; OPTIMAL CONTROL; STI;

BIOMEDICAL ENGINEERING;

ARTICLE; CASE STUDY; CD4+ T LYMPHOCYTE; CONTINUOUS PROCESS; DISEASE COURSE; HEALTH CARE COST; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNE SYSTEM; LONG TERM POTENTIATION; LYMPHOCYTE COUNT; MEDICINE; SIMULATION; STATISTICAL ANALYSIS; TREATMENT PLANNING; VIRUS LOAD;

EID: 33344455191     PISSN: 00189294     EISSN: None     Source Type: Journal    
DOI: 10.1109/TBME.2005.869651     Document Type: Article

References (26)

1. A. S. Perelson and P. W. Nelson, "Mathematical analysis of HIV-1 dynamics in vivo," SIAM, vol. 41, no. 1, pp. 3-14, 1999.
2. S. Bonhoeffer, M. Rembiszewski, G. M. Ortiz, and D. F. Nixon, "Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection," AIDS, vol. 14, pp. 2313-2322, 2000.
3. C. A. Janeway, Immunobiology. New York: Garland Churchill Livingstone, 2001.
4. M. A. Nowak and R. M. May, Virus Dynamics: Mathematical Principles of Immunology and Virology. Oxford, U.K.: Oxford Univ., 2000.
5. J. S. James. Human retroviruses and related infections, presented at Major U.S. Scientific AIDS Conf. [Online]. Available: http://www.aids.org/atn/a- 216-01.html
6. D. Wodarz and M. A. Nowak, "Specific therapy regimes could lead to long-term immunological control of HIV," PNAS, vol. 96, pp. 14464-14469, Dec. 1999.
7. _, (2003, Apr.) Treatment Interruptions. [Online]. Available: http://www.aids.org/factSheets/406-Treatment-Interruptions.html
8. J. S. James. (2003, Apr.). Treatment Interruption: Advanced HIV; Dr. Cal Cohen Interview on Retroviruses Conf. (Part 2 of 2). [Online]. Available: http://www.aids.org/atn/a-390-01.html
9. R. F. Stengel, R. Ghigliazza, N. Kulkarni, and O. Laplace, "Optimal control of a viral disease," in Proc. American Control Conf., vol. 5, Jun. 2001, pp. 3795-3800.
10. R. F. Stengel, R. Ghigliazza, and N. Kulkarni, "Optimal enhancement of immune response," Bioinformatics, vol. 18, pp. 1227-1235, Mar. 2002.
11. R. F. Stengel, R. Ghigliazza, N. Kulkarni, and O. Laplace, "Optimal control of innate immune response," Optimal Control Applicat. Methods, vol. 23. pp. 91-104, Jan. 2002.
12. M. E. Brandt and G. Chen, "Feedback control of a biodynamical model of HIV-1," IEEE Trans. Biomed. Eng., vol. 48, no. 7, pp. 754-759, Jul. 2001.
13. J. J. Kutch and P. Gurfil, "Optimal control of HIV infection with a continuously mutating viral population," in Proc. American Control Conference, vol. 5. Anchorage, AK, May 2002, pp. 4033-4038.
14. J. A. M. Felippe de Souza, M. A. L. Caetano, and T. Yoneyama, "Analysis of a sub-optimal scheme of drug dosage in the AIDS treatment," in Proc. American Control Conf., Denver, CO, Jun. 2003, pp. 1188-1193.
15. R. Zurakowski and A. R. Teel, "Enhancing immune response to HIV infection using MPC-based treatment scheduling," in Proc. American Control Conf., Denver, CO, June 2003, pp. 1182-1187.
16. H. Shim, S. J. Han, C. C. Chung, S. W. Nam, and J. H. Seo, "Optimal scheduling of drug treatment for HIV infection: continuous dose control and receding horizon control," Int. J. Control, Automation Syst., vol. 1, no. 3, pp. 282-288, September 2003.
17. A. M. Jeffrey, X. Xia, and I. K. Craig, "Controllability analysis of the chemotherapy of HIV/AIDS," presented at the IFAC, 15th Triennial World Congress, Barcelona, Spain, 2002.
18. _, "When to initiate HIV therapy: a control theoretic approach," IEEE Trans. Biomed. Eng., vol. 50, no. 11, pp. 1213-1220, Nov. 2003.
19. [ 19] S. Kubiak, H. Lehr, R. Levy, T. Moeller, A. Parker, and E. Swin. (2001) Modeling Control of HIV Infection Through Structured Treatment Interruptions With Recommendations for Experimental Protocol. CRSC. [Online]. Available: http://www.math.montana.edu/~parker, CRSC Tech. Rep. (CRSC-TR01-27)
20. A. Parker, private communication, Jan. 7, 2005.
21. D. Wodarz, private communication, Jan. 7, 2005.
22. A. Schwartz, "Theory and implementation of numerical methods based on Runge-Kutta integration for solving optimal control problems," Ph.D. dissertation, Univ. California, Berkeley, 1996.
23. D. E. Kirk, Optimal Control Theory: An Introduction. Englewood Cliffs, NJ: Prentice-Hall, 1970.
24. D. Wodarz, "Helper-dependent vs. helper-independent CTL responses in HIV infection: implications for drug therapy and resistance," J. Theoretical Biol., vol. 213, pp. 447-459, Aug. 2001.
25. D. Q. Mayne, J. B. Rawlings, C. V. Rao, and P. O. M. Scokaert, "Constrained model predictive control: stability and optimality," Automatica, vol. 36, pp. 789-814, 2000.
26. J. M. Lee and J. H. Lee, "Approximate dynamic programming strategies and their applicability for process control: a review and future directions," Int. J. Control, Automation Syst., vol. 2, no. 3, pp. 263-278, 2004.